UNCY Unicycive Therapeutics, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
11:27
Aug 15
Aug 15
The author is compiling a research thread of user-recommended non-AI tickers.
The author is compiling a research thread of user-recommended non-AI tickers, listing them as a factual watchlist
LOW
20:46
Jan 07
Jan 07
UNCY approval expected in 2026 with cash runway into 2027
Unicycive resubmitted after a CRL with only one issue and is expected to receive either a Class 1 approval in February 2026 or a Class 2 PDUFA decision by end of June 2026. The company's $42M cash plus $25M from warrants upon approval provides runway into 2027. The author expects to profit as with a prior similar biotech MIST.
HIGH
10:29
Jan 06
Jan 06
FDA approval could re-rate tiny hyperphosphatemia biotech
Author sees Unicycive's resubmitted NDA for Oxylanthanum Carbonate as likely to gain FDA approval because the prior CRL was CMC/manufacturing only, not safety or efficacy. If approved, the tiny ~$120M market cap could re-rate toward the $1–4B+ hyperphosphatemia opportunity and bull PTs around $40+. Main risk is binary FDA approval: the setup remains high-risk and gains depend on approval.
HIGH
About UNCY Investor Commentary
Across the available history and selected sources, Buzzberg tracks UNCY (Unicycive Therapeutics, Inc.) across 3 sources: 2 bullish vs 0 bearish calls from 3 authors. Historical directional balance: 67% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 3 total trade ideas tracked. Latest voices: thebigberbowski, u/RunningRobert1980, u/Low-Pollution-262.